An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants

Omicron variant of SARS-CoV-2 has become the predominant variant worldwide. VV116 is an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies. We conducted an open, prospective cohort study to evaluate its safety and effectiveness in Chinese participants infected with the omicron var...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yinzhong, Ai, Jingwen, Lin, Na, Zhang, Haocheng, Li, Yang, Wang, Hongyu, Wang, Sen, Wang, Zhen, Li, Tao, Sun, Feng, Fan, Zhenyu, Li, Liqun, Lu, Yunfei, Meng, Xianmin, Xiao, Hong, Hu, Huiliang, Ling, Yun, Li, Feng, Li, Hongdi, Xi, Chunmei, Gu, Liping, Zhang, Wenhong, Fan, Xiaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176639/
https://www.ncbi.nlm.nih.gov/pubmed/35579892
http://dx.doi.org/10.1080/22221751.2022.2078230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176639/
https://www.ncbi.nlm.nih.gov/pubmed/35579892
http://dx.doi.org/10.1080/22221751.2022.2078230

Ejemplares similares